Literature DB >> 8890706

Interleukin-6 receptor expression in the peripheral B cells of patients with multicentric Castleman's disease.

T Ishiyama1, M Koike, S Nakamura, T Kakimoto, Y Akimoto, N Tsuruoka.   

Abstract

Interleukin-6 (IL-6) is an important regulator of terminal B-cell differentiation. Inappropriate oversynthesis of IL-6 may play primary role in the pathogenesis of multicentric Castleman's disease (MCD). We investigated the expression of the IL-6 receptor (IL-6R) in peripheral B cells from three patients with MCD, as well as the responsiveness of these cells to IL-6. Flow-cytometric analysis showed that IL-6R was significantly expressed on the peripheral B cells of two of three patients. The B cells expressing IL-6R spontaneously produced increased levels of immunoglobulin G (IgG). IL-6R-expressing B cells from one patient showed hyper-responsiveness to IL-6.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8890706     DOI: 10.1007/s002770050224

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  3 in total

1.  FTY720 mediates activation suppression and G(0)/G (1) cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model.

Authors:  Xiangfeng Zeng; Tong Wang; Cairong Zhu; Yanxia Ye; Bing Song; Xinqiang Lai; Yaoying Zeng
Journal:  Inflamm Res       Date:  2012-03-10       Impact factor: 4.575

2.  Orbital pseudotumor as an initial manifestation of multicentric Castleman's disease.

Authors:  Masaru Inatani; Satoshi Kashii; Kazumasa Nosaka; Nobuyoshi Arima
Journal:  Jpn J Ophthalmol       Date:  2005 Nov-Dec       Impact factor: 2.447

3.  Optic neuropathy associated with Castleman disease.

Authors:  Ungsoo Kim; Jeong-Min Hwang
Journal:  Korean J Ophthalmol       Date:  2010-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.